• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Targets and patented drugs for chemotherapy of Chagas disease

Bioengineer by Bioengineer
January 17, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Chagas diseaseis a parasitic infection typically spread by triatomine vectors, affecting millions of people all over Latin America. Existing chemotherapy is centered on benznidazole and nifurtimox, providing unsatisfactory results and substantial side effects. The transmission of the disease by people migration has determined the emergence as a public health problem elsewhere in non-endemic countries of the word.So, the finding of novel ways to challenge this neglected disease is a main priority. Progress in scientific knowledge about Trypanosoma cruzi in the period comprising last 15-years has increased the identification of multiple targets for Chagas“ disease chemotherapy. Ergosterol biosynthesis pathway and cruzipain, the key cysteine protease (CP) of T.cruzi, considered as the best encouraging targets for trypanocidal drugs. Recent unfortunate clinical trials investigating the administration of pozoconazole and ravuconazole to chronic patients; an approach for the fast development of novel anti-T.cruzi chemotherapy focused on the CP inhibitor K777, which is close to entering the clinical trial phase. The combination of known drugs with existing trypanocidal agents and compounds recently identified as clinical candidates for Chagas disease can be considered among the finest points of the manuscript. In addition, trypanothione biosynthesis, thiol-dependant redox and polyamine metabolism, the glycolytic, glyconeogenic, pentose phosphate, lipidic and polyisoprenoid biosynthetic pathways, and specific enzymes from these biosynthetic pathways have been also specifically discussed. Novel synthesized anti-T. cruzi compounds with or without specific single or multi-target assigned have been also described in detail. In summary, loans on anti-Chagas disease agents focused to specific parasite targets as their metabolic pathways or specific enzymes have been summarized. Patent literature collected and published from 2000 to 2015, alleging inhibitors for specific T. cruzi targets or trypanocidal activity was achieved over the search database from Delphion Research intellectual property network including international patents and the European patent office, Espacenet.

###

For more information about the article, please visit https://benthamscience.com/journals/recent-patents-on-anti-infective-drug-discovery/volume/11/issue/2/page/74/

Reference: Duschak, VG.; (2016). Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period. Recent Patents on Anticancer Drug Discovery, DOI: 10.2174/1574891X11666161024165304

Media Contact

Faizan ul Haq
[email protected]
@BenthamScienceP

http://benthamscience.com/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Managing Anxiety During Menopause: The Uncertain Role of Hormone Therapy

October 21, 2025
Glutamate Deficit Affects Mouse Reproduction, Metabolism Sex-Specifically

Glutamate Deficit Affects Mouse Reproduction, Metabolism Sex-Specifically

October 21, 2025

Menopause Transition Linked to Elevated Risk of Eye Disease

October 21, 2025

Early Onset Natural Menopause Associated with Increased Risk of Metabolic Syndrome

October 21, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1269 shares
    Share 507 Tweet 317
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    302 shares
    Share 121 Tweet 76
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    129 shares
    Share 52 Tweet 32
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    125 shares
    Share 50 Tweet 31

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Managing Anxiety During Menopause: The Uncertain Role of Hormone Therapy

Glutamate Deficit Affects Mouse Reproduction, Metabolism Sex-Specifically

Menopause Transition Linked to Elevated Risk of Eye Disease

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 66 other subscribers
  • Contact Us

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.